search
Back to results

Evaluation of Enfilcon A Soft Contact Lens When Compared to Galyfilcon A Soft Contact Lens

Primary Purpose

Ametropia

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
enfilcon A
galyfilcon A
Sponsored by
Coopervision, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ametropia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Prior to being considered eligible to participate in this study, each subject MUST:

  • Be at least 18 years of age as of the date of evaluation for the study.
  • Have read the Informed Consent, been given an explanation of the Informed Consent, indicated understanding of the Informed Consent, signed the Informed Consent document.
  • Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments.
  • Be an adapted, current full-time silicone hydrogel or soft contact lens wearer. An adapted full-time wearer is defined as wearing contact lenses in both eyes on a daily basis for at least 8 hours per day for at least one month prior to participation in the study.
  • Possess wearable and visually functional eyeglasses.
  • Be in good general health, based on his/her knowledge.
  • Require spectacle lens powers between -1.00 and -6.00 diopters sphere with no more than 2.00 diopters of refractive astigmatism and be willing to wear contact lenses in both eyes.
  • Have: manifest refraction Snellen visual acuities (VA) equal to or better than 20/25 in each eye.
  • Upon completing the fitting process with the lenses to be worn in the study, have contact lens Snellen VA equal to or better than 20/30 in each eye.

Exclusion Criteria:

Subjects may not be enrolled in this study if any of the following apply: The subject is/has:

  • Wearing lenses in a monovision modality and is unwilling to be fit with distance lenses in both eyes. NOTE: Subjects may not wear lenses in a monovision modality at any time during the study as it will interfere with the visual acuity analysis.
  • Poor personal hygiene.
  • Any active participation in another clinical trial within 30 days prior to this study.
  • Currently pregnant (to the best of the subject's knowledge), is lactating or is planning a pregnancy within the study period.
  • A member, relative or household member of the investigator or of the investigational office staff.
  • Has a known sensitivity to ingredients used in the care products approved for use in the study.
  • Previous refractive surgery; or current or previous orthokeratology treatment.
  • Is aphakic or psuedophakic.
  • Ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome, lupus erythematosus, sclerodermia, keratoconus or type II diabetes.
  • The need for topical ocular medications or any medication which might interfere with contact lens wear or which would require the lenses to be removed during the day.
  • The presence of clinically significant (grade 3 or 4) anterior segment abnormalities.
  • Any; inflammations such as iritis; or any infection or allergic reaction of the eye, lids, or associated structures.
  • A known history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates or fungal infections.
  • A history of papillary conjunctivitis that has interfered with contact lens wear.
  • Slit lamp findings that would contraindicate contact lens wear, including but not limited to: Pathological dry eye or associated dry eye symptoms with decreased tear levels and punctuate staining > Grade 2, Pterygium, Corneal scars within the visual axis, Neovascularization or ghost vessels > 1.0 mm in from the limbus, Giant papillary conjunctivitis (GPC) of > Grade 1, Anterior uveitis or iritis, Seborrheic eczema, seborrheic conjunctivitis or blepharitis

To be eligible to be randomized for study product a subject must have ALL of the Inclusion Criteria and have NONE of the exclusion criteria present.

To be eligible for lens dispensing (either Test or Control), the subject's study lens contact lens visual acuity must be equal to or better than 20/30 in each eye.

Sites / Locations

  • Advanced Eyecare
  • Eric M. White, OD, Inc.
  • Vision Care Associates

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

enfilcon A

galyfilcon A

Arm Description

The test (experimental) lens is a silicone hydrogel contact lens following a daily wear 1 week planned replacement modality.

The control (active comparator) lens is a silicone hydrogel contact lens following a daily wear 1 week planned replacement modality.

Outcomes

Primary Outcome Measures

Objective Assessment: Ocular Response - Biomicroscopy
The primary safety endpoint are the objective slit lamp findings associated with the enfilcon A contact lenses compared with those same findings reported as associated with the galyfilcon A contact lenses. The incidence of biomicroscopy findings (0=not present, 4=severe) over the duration of the study with the highest reported grade was chosen for each unique eye. Biomicroscopy measurements were obtained at Baseline/Dispensing (baseline and dispensing visit combined), Post-Dispensing (after lenses were dispensed and allowed to settle) and All Follow-Ups (week 1 visit, week 2 visit, month 1 visit combined). The average grade for unique eyes with findings greater than 0 (none) is compared.
Comparison of Objective Findings - Number of Adverse Events in Unique Eyes
The primary safety endpoint are the objective findings of the number of adverse events in unique eyes associated with the enfilcon A contact lenses compared with those same findings as associated with the galyfilcon A contact lenses. The number of adverse events over the duration of the study was reported for each unique eye (bilateral or unilateral). Observations for adverse events were reported for any occurrence from Baseline through end of month 1 visit.

Secondary Outcome Measures

Full Information

First Posted
October 5, 2012
Last Updated
September 11, 2020
Sponsor
Coopervision, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01706770
Brief Title
Evaluation of Enfilcon A Soft Contact Lens When Compared to Galyfilcon A Soft Contact Lens
Official Title
Evaluation of Enfilcon A Soft Contact Lens Compared to Galyfilcon A Soft Contact Lens
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Completed
Study Start Date
May 2012 (undefined)
Primary Completion Date
July 2012 (Actual)
Study Completion Date
October 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Coopervision, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The primary objective of thes study is to confirm that the ocular response to the Test lenses are similar to those of the Control lenses when used in a 1 week planned replacement, daily wear modality over a 1-month period.
Detailed Description
The test lens and control lens were randomized in a 2:1 ratio to evaluate the test lens and control contact lens.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ametropia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
enfilcon A
Arm Type
Experimental
Arm Description
The test (experimental) lens is a silicone hydrogel contact lens following a daily wear 1 week planned replacement modality.
Arm Title
galyfilcon A
Arm Type
Active Comparator
Arm Description
The control (active comparator) lens is a silicone hydrogel contact lens following a daily wear 1 week planned replacement modality.
Intervention Type
Device
Intervention Name(s)
enfilcon A
Other Intervention Name(s)
Avaira® Toric
Intervention Type
Device
Intervention Name(s)
galyfilcon A
Other Intervention Name(s)
Acvuve® Advance®
Primary Outcome Measure Information:
Title
Objective Assessment: Ocular Response - Biomicroscopy
Description
The primary safety endpoint are the objective slit lamp findings associated with the enfilcon A contact lenses compared with those same findings reported as associated with the galyfilcon A contact lenses. The incidence of biomicroscopy findings (0=not present, 4=severe) over the duration of the study with the highest reported grade was chosen for each unique eye. Biomicroscopy measurements were obtained at Baseline/Dispensing (baseline and dispensing visit combined), Post-Dispensing (after lenses were dispensed and allowed to settle) and All Follow-Ups (week 1 visit, week 2 visit, month 1 visit combined). The average grade for unique eyes with findings greater than 0 (none) is compared.
Time Frame
Change from baseline/dispensing visits, post-dispensing visit and all follow-ups visits
Title
Comparison of Objective Findings - Number of Adverse Events in Unique Eyes
Description
The primary safety endpoint are the objective findings of the number of adverse events in unique eyes associated with the enfilcon A contact lenses compared with those same findings as associated with the galyfilcon A contact lenses. The number of adverse events over the duration of the study was reported for each unique eye (bilateral or unilateral). Observations for adverse events were reported for any occurrence from Baseline through end of month 1 visit.
Time Frame
Any occurrence from baseline to 1 month visit

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Prior to being considered eligible to participate in this study, each subject MUST: Be at least 18 years of age as of the date of evaluation for the study. Have read the Informed Consent, been given an explanation of the Informed Consent, indicated understanding of the Informed Consent, signed the Informed Consent document. Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments. Be an adapted, current full-time silicone hydrogel or soft contact lens wearer. An adapted full-time wearer is defined as wearing contact lenses in both eyes on a daily basis for at least 8 hours per day for at least one month prior to participation in the study. Possess wearable and visually functional eyeglasses. Be in good general health, based on his/her knowledge. Require spectacle lens powers between -1.00 and -6.00 diopters sphere with no more than 2.00 diopters of refractive astigmatism and be willing to wear contact lenses in both eyes. Have: manifest refraction Snellen visual acuities (VA) equal to or better than 20/25 in each eye. Upon completing the fitting process with the lenses to be worn in the study, have contact lens Snellen VA equal to or better than 20/30 in each eye. Exclusion Criteria: Subjects may not be enrolled in this study if any of the following apply: The subject is/has: Wearing lenses in a monovision modality and is unwilling to be fit with distance lenses in both eyes. NOTE: Subjects may not wear lenses in a monovision modality at any time during the study as it will interfere with the visual acuity analysis. Poor personal hygiene. Any active participation in another clinical trial within 30 days prior to this study. Currently pregnant (to the best of the subject's knowledge), is lactating or is planning a pregnancy within the study period. A member, relative or household member of the investigator or of the investigational office staff. Has a known sensitivity to ingredients used in the care products approved for use in the study. Previous refractive surgery; or current or previous orthokeratology treatment. Is aphakic or psuedophakic. Ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome, lupus erythematosus, sclerodermia, keratoconus or type II diabetes. The need for topical ocular medications or any medication which might interfere with contact lens wear or which would require the lenses to be removed during the day. The presence of clinically significant (grade 3 or 4) anterior segment abnormalities. Any; inflammations such as iritis; or any infection or allergic reaction of the eye, lids, or associated structures. A known history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates or fungal infections. A history of papillary conjunctivitis that has interfered with contact lens wear. Slit lamp findings that would contraindicate contact lens wear, including but not limited to: Pathological dry eye or associated dry eye symptoms with decreased tear levels and punctuate staining > Grade 2, Pterygium, Corneal scars within the visual axis, Neovascularization or ghost vessels > 1.0 mm in from the limbus, Giant papillary conjunctivitis (GPC) of > Grade 1, Anterior uveitis or iritis, Seborrheic eczema, seborrheic conjunctivitis or blepharitis To be eligible to be randomized for study product a subject must have ALL of the Inclusion Criteria and have NONE of the exclusion criteria present. To be eligible for lens dispensing (either Test or Control), the subject's study lens contact lens visual acuity must be equal to or better than 20/30 in each eye.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Scott E Schachter, OD
Organizational Affiliation
Unafiliated
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Cheryl Vincent-Reimer, OD
Organizational Affiliation
Unafiliated
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Eric White, OD
Organizational Affiliation
Unafiliated
Official's Role
Principal Investigator
Facility Information:
Facility Name
Advanced Eyecare
City
Pismo Beach
State/Province
California
ZIP/Postal Code
93449
Country
United States
Facility Name
Eric M. White, OD, Inc.
City
San Diego
State/Province
California
ZIP/Postal Code
48823
Country
United States
Facility Name
Vision Care Associates
City
East Lansing
State/Province
Michigan
ZIP/Postal Code
48823
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Evaluation of Enfilcon A Soft Contact Lens When Compared to Galyfilcon A Soft Contact Lens

We'll reach out to this number within 24 hrs